Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study

Rasmus Rask Kragh Jørgensen; Lasse Hjort Jakobsen; Sandra Eloranta; Karin E Smedby; Robert Schou Pedersen; Judit M Jørgensen; Michael Roost Clausen; Peter Brown; Anne Ortved Gang; Inger-Lise Gade; Thomas Stauffer Larsen; Mats Jerkeman; Tarec Christoffer El-Galaly

doi:10.1111/ejh.14275

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study

Rasmus Rask Kragh Jørgensen^*, Lasse Hjort Jakobsen, Sandra Eloranta, Karin E Smedby, Robert Schou Pedersen, Judit M Jørgensen, Michael Roost Clausen, Peter Brown, Anne Ortved Gang, Inger-Lise Gade, Thomas Stauffer Larsen, Mats Jerkeman, Tarec Christoffer El-Galaly

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

3 Citations (Scopus)

79 Downloads (Pure)

Abstract

PURPOSE: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.

PATIENTS AND METHODS: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18-60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).

RESULTS: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%-76%) and 79% (CI;73%-85%) versus 62% (CI;55%-70%) and 76% (CI;69%-82%) for R-CHOP (log-rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%-74%) and 79% (CI; 72%-84%) for R-CHOEP versus 63% (CI; 55%-73%) and 79% (CI;72%-87%) for R-CHOP (log-rank test, PFS p = .90 and OS p = .63).

CONCLUSION: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.

Original language	English
Book series	European Journal of Haematology
Volume	113
Issue number	5
Pages (from-to)	641-650
Number of pages	10
ISSN	0902-4506
DOIs	https://doi.org/10.1111/ejh.14275
Publication status	Published - Nov 2024

Bibliographical note

Keywords

DLBCL
R-CHOP vs R-CHOEP
lymphoma
optimizing treatment outcome
real world data
toxicity after treatment
treatment of high-risk patients

Access to Document

10.1111/ejh.14275Licence: CC BY-NC 4.0

Jørgensen et al. (2024). Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma - A Danish observational population-based studyFinal published version, 1.33 MBLicence: CC BY-NC 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Rask Kragh Jørgensen, R., Jakobsen, L. H., Eloranta, S., Smedby, K. E., Pedersen, R. S., Jørgensen, J. M., Clausen, M. R., Brown, P., Gang, A. O., Gade, I.-L., Larsen, T. S., Jerkeman, M., & El-Galaly, T. C. (2024). Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study. European Journal of Haematology, 113(5), 641-650. https://doi.org/10.1111/ejh.14275

@article{95aae21bfdf64a15be1d47ff26340ffa,

title = "Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study",

abstract = "PURPOSE: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.PATIENTS AND METHODS: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18-60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).RESULTS: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69\% (95\% Confidence intervals [CI]; 63\%-76\%) and 79\% (CI;73\%-85\%) versus 62\% (CI;55\%-70\%) and 76\% (CI;69\%-82\%) for R-CHOP (log-rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65\% (CI; 57\%-74\%) and 79\% (CI; 72\%-84\%) for R-CHOEP versus 63\% (CI; 55\%-73\%) and 79\% (CI;72\%-87\%) for R-CHOP (log-rank test, PFS p = .90 and OS p = .63).CONCLUSION: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.",

keywords = "DLBCL, R-CHOP vs R-CHOEP, lymphoma, optimizing treatment outcome, real world data, toxicity after treatment, treatment of high-risk patients",

author = "\{Rask Kragh J{\o}rgensen\}, Rasmus and Jakobsen, \{Lasse Hjort\} and Sandra Eloranta and Smedby, \{Karin E\} and Pedersen, \{Robert Schou\} and J{\o}rgensen, \{Judit M\} and Clausen, \{Michael Roost\} and Peter Brown and Gang, \{Anne Ortved\} and Inger-Lise Gade and Larsen, \{Thomas Stauffer\} and Mats Jerkeman and El-Galaly, \{Tarec Christoffer\}",

note = "{\textcopyright} 2024 The Author(s). European Journal of Haematology published by John Wiley \& Sons Ltd.",

year = "2024",

month = nov,

doi = "10.1111/ejh.14275",

language = "English",

volume = "113",

pages = "641--650",

journal = "European Journal of Haematology",

issn = "0902-4506",

publisher = "Wiley-Blackwell",

number = "5",

}

Rask Kragh Jørgensen, R , Jakobsen, LH, Eloranta, S, Smedby, KE, Pedersen, RS, Jørgensen, JM, Clausen, MR, Brown, P, Gang, AO, Gade, I-L, Larsen, TS, Jerkeman, M & El-Galaly, TC 2024, 'Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study', European Journal of Haematology, vol. 113, no. 5, pp. 641-650. https://doi.org/10.1111/ejh.14275

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study. / Rask Kragh Jørgensen, Rasmus ; Jakobsen, Lasse Hjort; Eloranta, Sandra et al.
In: European Journal of Haematology, Vol. 113, No. 5, 11.2024, p. 641-650.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study

AU - Rask Kragh Jørgensen, Rasmus

AU - Jakobsen, Lasse Hjort

AU - Eloranta, Sandra

AU - Smedby, Karin E

AU - Pedersen, Robert Schou

AU - Jørgensen, Judit M

AU - Clausen, Michael Roost

AU - Brown, Peter

AU - Gang, Anne Ortved

AU - Gade, Inger-Lise

AU - Larsen, Thomas Stauffer

AU - Jerkeman, Mats

AU - El-Galaly, Tarec Christoffer

PY - 2024/11

Y1 - 2024/11

N2 - PURPOSE: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.PATIENTS AND METHODS: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18-60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).RESULTS: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%-76%) and 79% (CI;73%-85%) versus 62% (CI;55%-70%) and 76% (CI;69%-82%) for R-CHOP (log-rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%-74%) and 79% (CI; 72%-84%) for R-CHOEP versus 63% (CI; 55%-73%) and 79% (CI;72%-87%) for R-CHOP (log-rank test, PFS p = .90 and OS p = .63).CONCLUSION: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.

AB - PURPOSE: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.PATIENTS AND METHODS: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18-60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).RESULTS: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%-76%) and 79% (CI;73%-85%) versus 62% (CI;55%-70%) and 76% (CI;69%-82%) for R-CHOP (log-rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%-74%) and 79% (CI; 72%-84%) for R-CHOEP versus 63% (CI; 55%-73%) and 79% (CI;72%-87%) for R-CHOP (log-rank test, PFS p = .90 and OS p = .63).CONCLUSION: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.

KW - DLBCL

KW - R-CHOP vs R-CHOEP

KW - lymphoma

KW - optimizing treatment outcome

KW - real world data

KW - toxicity after treatment

KW - treatment of high-risk patients

UR - https://www.scopus.com/pages/publications/85199105677

U2 - 10.1111/ejh.14275

DO - 10.1111/ejh.14275

M3 - Journal article

C2 - 39037054

SN - 0902-4506

VL - 113

SP - 641

EP - 650

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 5

ER -

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Advanced statistical methods for studies of lymphoma prognosis and treatment outcomes in a real-world setting

Cite this